Mind the Gap in Kidney Care: Translating What We Know into What We Do

Main Article Content

Valerie A. Luyckx
Katherine R. Tuttle
Dina Abdellatif
Ricardo Correa-Rotter
Winston W.S Fung
Agnès Haris
Li-Li Hsiao
Makram Khalife
Latha A. Kumaraswami
Fiona Loud
Vasundhara Raghavan
Stefanos Roumeliotis
Marianella Sierra
Ifeoma Ulasi
Bill Wang
Siu-Fai Lui
Vassilios Liakopoulos
Alessandro Balducci

Abstract

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition,  because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

Article Details

How to Cite
Luyckx , V. A., Tuttle, K. R., Abdellatif, D., Correa-Rotter, R., Fung, W. W., Haris, A., Hsiao, L.-L., Khalife, M., Kumaraswami, L. A. ., Loud, F., Raghavan, V., Roumeliotis, S., Sierra, M., Ulasi, I., Wang, B., Lui, S.-F., Liakopoulos , V., & Balducci, A. (2024). Mind the Gap in Kidney Care: Translating What We Know into What We Do. Journal of the Nephrology Society of Thailand, 30(2), 81–96. Retrieved from https://he01.tci-thaijo.org/index.php/JNST/article/view/270199
Section
Special Article

References

Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-50.

Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Accessed November 18, 2023. http://vizhub.healthdata.org/gbd-compare.

Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414-22D.

International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. Accessed November 18, 2023. https://www. theisn.org/initiatives/global-kidney-health-atlas/.

GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393-409.

Nguyen-Thi HY, Le-Phuoc TN, Phat NT, Van DT, Le-Thi TT, Tu Le ND, et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights. 2021;14:11786329211036011.

US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronic-kidneydisease/6-healthcare-expenditures-for-persons-with-ckd.

Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. Accessed January 16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf.

Ke C, Liang J, Liu M, Liu S, Wang C. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. BMC Nephrol. 2022;23(1):17.

Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet. 2023;401(10384):1302-12.

Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019;394(10199):652-62.

Chu L, Bhogal SK, Lin P, Steele A, Fuller M, Ciaccia A, et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022;46(5):464-72.

Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390(10105):1888-1917.

Stengel B, Muenz D, Tu C, Speyer E, de Pinho NA, Combe C, et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep. 2020;6(2):437-48.

Chu CD, Chen MH, McCulloch CE, Powe NR, Estrella MM, Shlipak MG, et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med. 2021;3(4):576-85.e1.

Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-19.

Gummidi B, John O, Ghosh A, Modi GK, Sehgal M, Kalra OP, et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep. 2020;5(12):2246-55.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127.

Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ, et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab. 2023;25(10):2970-9.

Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, et al. Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2017;70(3):337-46.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87.

Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2(12):e1918169.

Ismail WW, Witry MJ, Urmie JM. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm. 2023;29(5):449-63.

Heerspink HJL, Vart P, Jongs N, Neuen BL, Bakris G, Claggett B, et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023;25(11):3327-36.

Nuffield Department of Population Health Renal Studies Group; SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-1801.

Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023;16(8):1187-98.

McEwan P, Boyce R, Sanchez JJG, Sjöström CD, Stefansson B, Nolan S, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant. 2023;38(5):1260-70.

Vanholder R, Annemans L, Braks M, Brown EA, Pais P, Purnell TS, et al. Inequities in kidney health and kidney care. Nat Rev Nephrol. 2023;19(11):694-708.

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84.

Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103(4):772-81.

Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA. 2023;329(16):1333-6.

World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCD-GAP). Accessed November 18, 2023. https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gap-final-report.pdf?sfvrsn=55b22b89_5&download=true

Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet. 2018;392(10160):2203-12.

Kingori P, Grietens KP, Abimbola S, Ravinetto R. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health. 2023;6(Suppl 3):e012902.

Pan American Health Organization Quality control of medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines.

Tuttle KR, Wong L, St Peter W, Roberts G, Rangaswami J, Mottl A, et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol. 2022;17(7):1092-1103.

Kalyesubula R, Conroy AL, Calice-Silva V, Kumar V, Onu U, Batte A, et al. Screening for kidney disease in low- and middleincome countries. Semin Nephrol. 2022;42(5):151315.

Francis A, Hafidz MIA, Ekrikpo UE, Chen T, Wijewickrama E, Tannor EK, et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int. 2022;102(5):969-73.

Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renalmetabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes. 2020;13(11):e007264.

Neumiller JJ, Alicic RZ, Tuttle KR. Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis. 2021;28(4):318-27.

Mishra SR, Neupane D, Preen D, Kallestrup P, Perry HB. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health. 2015;10:11:43.

Joshi R, John O, Jha V. The potential impact of public health interventions in preventing kidney disease. Semin Nephrol. 2017;37(3):234-44.

Patel A, Praveen D, Maharani A, Oceandy D, Pilard Q, Kohli MPS, et al. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol. 2019;4(10):978-86.

Ardavani A, Curtis F, Khunti K, Wilkinson TJ. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep. 2023;6(1):e1064.

Sherrod CF, Farr SL, Sauer AJ. Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?. Eur Heart J. 2023;44(22):1970-2.

Ramakrishnan C, Tan NC, Yoon S, Hwang SJ, Foo MWY, Paulpandi M, et al. Healthcare professionals’ perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Serv Res. 2022;22(1):560.

Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38(1):147-55.

Peralta CA, Livaudais-Toman J, Stebbins M, Lo L, Robinson A, Pathak S, et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis. 2020;76(5):636-44.

Rios P, Sola L, Ferreiro A, Silvariño R, Lamadrid V, Ceretta L, et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One. 2022;17(10):e0266617.

Stevenson JK, Campbell ZC, Webster AC, Chow CK, Tong A, Craig JC, et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev. 2019;8(8):CD012379.

Tuot DS, Crowley ST, Katz LA, Leung J, Alcantara-Cadillo DK, Ruser C, et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res. 2022;6(9):e40001.

Verberne WR, Stiggelbout AM, Bos WJW, van Delden JJM. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics. 2022;23(1):47.

Taha A, Iman Y, Hingwala J, Askin N, Mysore P, Rigatto C, et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med. 2022;4(10):100540.

Essue BM, Laba TL, Knaul F, Chu A, Minh HV, Nguyen TKP, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. in: D.T. Jamison, H. Gelband, S. Hortonet al. (Eds.), Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. https://doi.org/10.1596/978-1-4648-0527-1_ch6

Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387(10013):61-9.

Kamath N, Iyengar AA. Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr. 2017;84(11):822-5.

Cirillo L, Ravaglia F, Errichiello C, Anders HJ, Romagnani P, Becherucci F. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol. 2022;37(12):2997-3008.

Donohue JF, Elborn JS, Lansberg P, Javed A, Tesfaye S, Rugo H, et al. Bridging the “know-do” gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh. 2023;15:103-19.

Population Health Research Institute. Polypills added to WHO essential medicines list. Accessed November 18, 2023. https://www.phri.ca/eml/.

Sepanlou SG, Mann JFE, Joseph P, Pais P, Gao P, Sharafkhah M, et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol. 2023;18(11):1408-15.

Dev V, Mittal A, Joshi V, Meena JK, Goel AD, Didel S, et al. Cost analysis of telemedicine use in paediatric nephrologythe LMIC perspective. Pediatr Nephrol. 2024;39(1):193-201.

Musacchio N, Zilich R, Ponzani P, Guaita G, Giorda C, Heidbreder R, et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes. 2023;15(3):224-36.

Zuniga C, Riquelme C, Muller H, Vergara G, Astorga C, Espinoza M. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep. 2020;5(6):920-3.

van der Horst DEM, Hofstra N, van Uden-Kraan CF, Stiggelbout AM, van den Dorpel MA, Pieterse AH, et al. Shared decision making in health care visits for CKD: patients’ decisional role preferences and experiences. Am J Kidney Dis. 2023;82(6):677-86.

Hole B, Scanlon M, Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J. 2023;16(Suppl 1):i12-i19.